Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;2(4):144-148.
doi: 10.5114/ceh.2016.63871. Epub 2016 Nov 28.

Prevalence of HCV genotypes in Poland - the EpiTer study

Robert Flisiak  1 , Joanna Pogorzelska  1 , Hanna Berak  2 , Andrzej Horban  2 , Iwona Orłowska  3 , Krzysztof Simon  3 , Ewelina Tuchendler  4 , Grzegorz Madej  4 , Anna Piekarska  5 , Maciej Jabłkowski  6 , Zbigniew Deroń  7 , Włodzimierz Mazur  8 , Marcin Kaczmarczyk  8 , Ewa Janczewska  9 , Arkadiusz Pisula  9 , Jacek Smykał  10 , Krzysztof Nowak  10 , Marek Matukiewicz  10 , Waldemar Halota  11 , Joanna Wernik  11 , Katarzyna Sikorska  12 , Iwona Mozer-Lisewska  13 , Błażej Rozpłochowski  13 , Aleksander Garlicki  14 , Krzysztof Tomasiewicz  15 , Joanna Krzowska-Firych  15 , Barbara Baka-Ćwierz  16 , Wiesław Kryczka  17 , Dorota Zarębska-Michaluk  17 , Iwona Olszok  18 , Anna Boroń-Kaczmarska  19 , Barbara Sobala-Szczygieł  19 , Bronisława Szlauer  20 , Bogumiła Korcz-Ondrzejek  20 , Jerzy Sieklucki  21 , Robert Pleśniak  21 , Agata Ruszała  21 , Barbara Postawa-Kłosińska  22 , Jolanta Citko  23 , Anna Lachowicz-Wawrzyniak  24 , Joanna Musialik  25 , Edyta Jezierska  26 , Witold Dobracki  27 , Beata Dobracka  27 , Jan Hałubiec  28 , Rafał Krygier  29 , Anna Strokowska  30 , Wojciech Chomczyk  30 , Krystyna Witczak-Malinowska  31
Affiliations

Prevalence of HCV genotypes in Poland - the EpiTer study

Robert Flisiak et al. Clin Exp Hepatol. 2016 Dec.

Abstract

The aim of the study: Was to assess current prevalence of hepatitis C virus (HCV) genotypes in Poland, including their geographic distribution and changes in a given period of time.

Material and methods: Data were collected with questionnaires from 29 Polish centers and included data of patients diagnosed with HCV infection between 1 January 2013 and 31 March 2016.

Results: In total, data of 9800 patients were reported. The highest prevalence was estimated for genotype 1b (81.7%), followed by 3 (11.3%), 4 (3.5%), 1a (3.2%) and 2 (0.2%). Genotype 5 or 6 was reported in 6 patients only (0.1%). The highest prevalence of genotype 1 was observed in central (łódzkie, mazowieckie, świętokrzyskie), eastern (lubelskie) and southern (małopolskie, śląskie) Poland. The highest rate for genotype 3 was observed in south-western (dolnośląskie, lubuskie) and eastern (podlaskie, warmińsko-mazurskie and podkarpackie) Poland. Compared to historical data, we observed an increasing tendency of G1 prevalence from 72.0% in 2003 to 87.5% in 2016, which was accompanied by a decrease of G3 (17.9% vs. 9.1%) and G4 (9.0% vs. 3.1%).

Conclusions: Almost 85% of patients with HCV in Poland are infected with genotype 1 (almost exclusively subgenotype 1b), and its prevalence shows an increasing tendency, accompanied by a decrease of genotypes 3 and 4.

Keywords: epidemiology; hepatitis C; infection; liver.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of HCV genotypes in 9800 Polish patients enrolled for treatment of chronic hepatitis C between 1 January 2013 and 31 March 2016 in 29 centers. Estimations of G1a and G1b prevalence in all G1 patients based on the proportion of subgenotypes among those subgenotyped (G1a/G1b: 4/96) are shown in brackets
Fig. 2
Fig. 2
Annual changes in distribution of HCV genotypes between 2013 and 2016 in Poland
Fig. 3
Fig. 3
Changes in prevalence of HCV genotype 1a between 2013 and 2016 in selected voivodeships with the highest prevalence of this subgenotype
Fig. 4
Fig. 4
Changes in prevalence of HCV genotype 3 between 2013 and 2016 in selected voivodeships with the highest prevalence of this subgenotype
Fig. 5
Fig. 5
Changes in prevalence of HCV genotype 4 between 2013 and 2016 in selected voivodeships with the highest prevalence of this subgenotype
See this image and copyright information in PMC

References

    1. Flisiak R, Halota W, Horban A, et al. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol. 2011;23:1213–1217. - PubMed
    1. Flisiak R, Halota W, Tomasiewicz K, et al. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol. 2015;27:70–76. - PubMed
    1. Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol. 2016;2:34–37. - PMC - PubMed
    1. Jaroszewicz J, Flisiak R, Dusheiko G. A pill for HCV – myth or foreseeable future? Liver Int. 2014;34:6–11. - PubMed
    1. Jaroszewicz J, Flisiak-Jackiewicz M, Lebensztejn D, et al. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opin Investig Drugs. 2015;24:1229–1239. - PubMed